Item 2.02. Results of Operations and Financial Condition.

On April 28, 2022, BeiGene, Ltd. (the "Company") filed its 2021 Annual Report for the year ended December 31, 2021 (the "STAR Annual Report") with the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange, which was prepared in accordance with the listing rules of the STAR Market and the applicable securities laws and regulations of the Peoples' Republic of China (the "PRC" and the "PRC Securities Laws").

As required by the PRC Securities Laws, the STAR Annual Report contains additional financial information of the Company regarding the Company's gross profit margin ratio, research and development expenses allocated by key products and other research and development projects, and production, sales and inventory stock units of key products, for the year ended December 31, 2021 (the "Reporting Period"), prepared in accordance with the China Accounting Standards for Business Enterprises - Basic Standard ("CAS") and other applicable PRC accounting rules, guidance and interpretations (together with CAS, "PRC GAAP"). As required by the PRC Securities Laws, the STAR Annual Report also contains financial information of the Company for the Reporting Period prepared in accordance with PRC GAAP. PRC GAAP are different from accounting principles generally accepted in the United States ("U.S. GAAP"). The financial information regarding the Company's research and development expenses allocated by key products and other research and development projects for the Reporting Period and the Company's production, sales and inventory stock units of key products for the Reporting Period prepared in accordance with U.S. GAAP as well as a summary of the material differences between PRC GAAP and U.S. GAAP are attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The STAR Annual Report is available to the public in Chinese language only on the website maintained by the Shanghai Stock Exchange at www.sse.com.cn. The STAR Annual Report and the information contained on the Shanghai Stock Exchange's website are not part of this Current Report on Form 8-K and shall not be deemed filed or furnished by the Company with the U.S. Securities and Exchange Commission, nor shall they be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Securities Exchange Act of 1934, as amended (the "Exchange Act").

The information in Item 2.02 of this Current Report on Form 8-K and in Exhibit 99.1 is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01. Other Events.

On April 27, 2022, the Company issued a press release announcing that the Independent Data Monitoring Committee (IDMC) determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the study's primary endpoint of overall survival (OS) in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). A copy of this press release is attached hereto as Exhibit 99.2, and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Financial Information, furnished herewith

       99.2               Press release titled "Global Phase 3 Trial of BeiGene's PD-1 Inhibitor,
                          Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in
                          First-Line Advanced Esophageal Squamous Cell Carcinoma" issued by BeiGene,
                          Ltd. on April 27, 2022.

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses